Nymox Pharmaceutical Corp. (Nasdaq: NYMX) reported positive results from a Phase 3 study of NX-1207 sending the stock price soaring $1.67 to $2.94.
Nymox reports positive study results
July 27, 2015 at 07:47 AM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.